InspireMD (NYSE:NSPR) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Wednesday. The firm issued a sell rating on the stock.

InspireMD Price Performance

Shares of NYSE:NSPR opened at $1.99 on Wednesday. The firm has a market capitalization of $46.57 million, a PE ratio of -1.84 and a beta of 0.83. The business has a 50-day moving average of $2.37 and a two-hundred day moving average of $2.67. InspireMD has a 12 month low of $1.03 and a 12 month high of $3.85.

InspireMD (NYSE:NSPR) last announced its quarterly earnings results on Wednesday, March 6th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.04. The company had revenue of $1.76 million during the quarter, compared to analyst estimates of $1.65 million. InspireMD had a negative return on equity of 55.71% and a negative net margin of 320.97%. During the same period in the prior year, the firm posted ($0.60) earnings per share. As a group, research analysts anticipate that InspireMD will post -0.61 earnings per share for the current year.

Institutional Investors Weigh In On InspireMD

Several institutional investors and hedge funds have recently modified their holdings of NSPR. McKinley Carter Wealth Services Inc. purchased a new stake in shares of InspireMD in the fourth quarter worth about $28,000. Avestar Capital LLC purchased a new stake in shares of InspireMD in the third quarter worth about $65,000. Finally, Mesirow Financial Investment Management Inc. purchased a new stake in shares of InspireMD in the first quarter worth about $71,000. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.